Keybanc Maintains Overweight on Avanos Medical, Lowers Price Target to $47
Keybanc analyst Matthew Mishan maintains Avanos Medical (NYSE:AVNS) with a Overweight and lowers the price target from $55 to $47.
Avanos Medical Shares Fall As Higher Transportation Costs Hit Q2 Margins; Lowers FY21 Guidance
Avanos Medical Inc (NYSE:AVNS) reported a second-quarter FY21 adjusted EPS of $0.21, missing the consensus of $0.23. The sales of $186.4…
Avanos Narrows FY21 Adj. EPS Guidance From $1.10-$1.25 To $1.10-$1.20 vs $1.21 Est.
Full Year 2021 Outlook
The company maintains its outlook for net sales to increase 2 to 4 percent, on a constant currency basis, compared to 2020. The company is revising its previously announced
Earnings Scheduled For August 3, 2021
Companies Reporting Before The Bell
• Myriad Genetics (NASDAQ:MYGN) is likely to report earnings for its fourth quarter.
• Stellantis (NYSE:STLA) is expected to report earnings for its second quarter.
Earnings Scheduled For May 7, 2021
Companies Reporting Before The Bell
• Cronos Group (NASDAQ:CRON) is likely to report earnings for its first quarter.
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.